Skip to main content

aCSCC: with immunotherapy it can be cured

By 12 Dicembre 2019Maggio 12th, 2021No Comments

Which are the aCSCC eligible patients for cemiplimab and how to identify them? What is the incidence of advanced cutaneous squamous cell carcinoma and what are the advantages of using cemiplimab compared to chemotherapy? We asked Claus Garbe (Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University, Tuebingen) during Immunotherapy Bridge 2019.